Spastic paraplegia type 5A
Dernière mise à jour 19 mars 2026
Respecte les directives éditoriales
- TéléchargerTélécharger
- Partager
- Language
- Discussion
- Ask Patient
- Version audio
- Ajouter aux sources préférées sur Google
Spastic paraplegia type 5A belongs to a group of genetic disorders known as hereditary spastic paraplegias. These disorders are characterised by muscle stiffness (spasticity) and severe weakness in the lower limbs (paraplegia). Hereditary spastic paraplegias are often divided into two types: pure and complex. The pure types involve spasticity and weakness only in the lower limbs, while the complex types involve additional problems with other areas of the body. Additional features can include changes in vision, changes in intellectual functioning, brain abnormalities, and disturbances in nerve function (neuropathy). Spastic paraplegia type 5A is usually classified as a pure hereditary spastic paraplegia, although complex-type features have been reported in some individuals.
Sélections vidéo pour Conditions génétiquesBibliothèque vidéo
Description
Spastic paraplegia type 5A belongs to a group of genetic disorders known as hereditary spastic paraplegias. These disorders are characterised by muscle stiffness (spasticity) and severe weakness in the lower limbs (paraplegia). Hereditary spastic paraplegias are often divided into two types: pure and complex. The pure types involve spasticity and weakness only in the lower limbs, while the complex types involve additional problems with other areas of the body. Additional features can include changes in vision, changes in intellectual functioning, brain abnormalities, and disturbances in nerve function (neuropathy). Spastic paraplegia type 5A is usually classified as a pure hereditary spastic paraplegia, although complex-type features have been reported in some individuals.
The signs and symptoms of spastic paraplegia type 5A usually appear in adolescence, but they can begin at any time between infancy and mid-adulthood. In addition to spasticity and weakness, people with spastic paraplegia type 5A can lose the ability to sense the position of their limbs or detect vibrations with their lower limbs. They may also have muscle wasting (amyotrophy), reduced bladder control, or high arches of the feet (pes cavus). Some affected individuals have low bone density (osteopenia) or vitamin D deficiency. Affected individuals eventually require walking support, usually around 20 years after symptoms begin, or wheelchair assistance, around 30 years after symptoms begin.
Inheritance patterns
The source lists the following possible inheritance patterns: Autosomal recessive. More than one pattern can apply in different cases.
Related genes
Other names
Autosomal recessive spastic paraplegia 5A
Spastic paraplegia 5
Spastic paraplegia 5A
SPG5
SPG5A
Related patient information and medicines

Patient information leaflet
Paralysie cérébrale
Cerebral palsy is a problem with muscle function. It is caused by brain injury or abnormal development of the brain that occurs while a child's brain is still developing. Cerebral palsy is a name for a group of life-long conditions that have problems with muscle function and control. Some people with cerebral palsy ... Types of cerebral palsy.

Patient information leaflet
Dystonie
A dystonie is a lasting or frequently recurring and unwanted (involuntary) muscle contraction. It can affect one or more muscles in the body. There is no cure; however, there are different types of treatment which can help. Secondary dystonia Secondary means the dystonia ... It is not caused by your genetic make-up. Some neurological conditions.

Patient information leaflet
Lésion nerveuse après injection épidurale
A spinal injection Spinal anaesthetic is given directly into the fluid that surrounds your spinal cord (called the cerebrospinal fluid). The injection can be a local anaesthetic or a medicine to relieve pain. The risk of longer... Lésion nerveuse to both legs (paraplegia) ou death occurs between 1 in 54,500 to 1 in 141,500 spinal or epidural.

Patient information leaflet
Soulagement de la douleur par epidurale après la chirurgie
The content of this leaflet is used with the permission of the Royal College of Anaesthetists , the professional body responsible for the speciality throughout the UK, ensuring the quality of patient care through the maintenance of standards in anaesthesia, critical care and pain medicine. What is an epidural. An epidural is used for giving pain.

Patient information leaflet
Maladie osseuse de Paget
Paget's disease of bone affects the structure of parts of one or more bones. In most cases it causes no symptoms and does not need treatment. Symptoms develop in some cases and pain in the affected part of bone... What is Paget's disease of bone. Paget's disease of bone was first described by Sir James Paget dans 1877. (It is a different condition.

Patient information leaflet
syndrome d'Ehlers-Danlos
It is not possible to generalise about the degree of learning difficulty that children experience as th... Musculocontractural Ehlers-Danlos syndrome Musculocontractural EDS (mcEDS) is a rare type of EDS in which muscles in the legs and arms are severely tightened and shortened - these are called muscle contractures. The skin is severely affected.
Lectures complémentaires et références
- Spastic paraplegia type 5A; MedlinePlus, National Library of Medicine.
- Chou CT, Soong BW, Lin KP, Tsai YS, Jih KY, Liao YC, Lee YC. Clinical characteristics of Taiwanese patients with Hereditary spastic paraplegia type 5. Ann Clin Transl Neurol. 2020 Apr;7(4):486-496. doi: 10.1002/acn3.51019. Epub 2020 Mar 22.
- Ehnert S, Hauser S, Hengel H, Hoflinger P, Schule R, Lindig T, Baets J, Deconinck T, de Jonghe P, Histing T, Nussler AK, Schols L, Rattay TW. Vitamin D3 deficiency and osteopenia in spastic paraplegia type 5 indicate impaired bone homeostasis. Sci Rep. 2024 Mar 27;14(1):7335. doi: 10.1038/s41598-024-53057-5.
- Gasser T, Finsterer J, Baets J, Van Broeckhoven C, Di Donato S, Fontaine B, De Jonghe P, Lossos A, Lynch T, Mariotti C, Schols L, Spinazzola A, Szolnoki Z, Tabrizi SJ, Tallaksen CM, Zeviani M, Burgunder JM, Harbo HF; EFNS. EFNS guidelines on the molecular diagnosis of ataxias and spastic paraplegias. Eur J Neurol. 2010 Feb;17(2):179-88. doi: 10.1111/j.1468-1331.2009.02873.x. Epub 2009 Dec 28.
- Hedera P. Uncomplicated (Pure) Hereditary Spastic Paraplegia Overview. 2000 Aug 15 [updated 2025 Jun 5]. In: Adam MP, Bick S, Mirzaa GM, Wallace SE, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2026. Available from http://www.ncbi.nlm.nih.gov/books/NBK1509/
- Pashaei M, Davarzani A, Hajati R, Zamani B, Nafissi S, Larti F, Nilipour Y, Rohani M, Alavi A. Description of clinical features and genetic analysis of one ultra-rare (SPG64) and two common forms (SPG5A and SPG15) of hereditary spastic paraplegia families. J Neurogenet. 2021 Mar-Jun;35(2):84-94. doi: 10.1080/01677063.2021.1895146. Epub 2021 Mar 26.
- Perez-Torre P, Garcia Galloway E, Lopez-Sendon Moreno JL. Hereditary spastic paraparesis due to SPG5/CYP7B1 mutation with potential therapeutic implications. Neurologia (Engl Ed). 2023 Nov-Dec;38(9):710-711. doi: 10.1016/j.nrleng.2023.10.005. Epub 2023 Oct 17. No abstract available.
- Resch D, Alecu JE, Yang K, Quiroz V, Schierbaum L, Bernardi K, Zaman Z, Agianda HAP, Rong J, Battaglia N, Carty S, Tam A, Kieslich M, Santorelli FM, Gonzalez-Salazar C, Franca Junior MC, Ebrahimi-Fakhari D. Spectrum of Movement Disorders in Early-Onset Hereditary Spastic Paraplegia: A Study of 428 Cases. Mov Disord. 2026 Mar;41(3):615-624. doi: 10.1002/mds.70141. Epub 2025 Dec 2.
- Schols L, Rattay TW, Martus P, Meisner C, Baets J, Fischer I, Jagle C, Fraidakis MJ, Martinuzzi A, Saute JA, Scarlato M, Antenora A, Stendel C, Hoflinger P, Lourenco CM, Abreu L, Smets K, Paucar M, Deconinck T, Bis DM, Wiethoff S, Bauer P, Arnoldi A, Marques W, Jardim LB, Hauser S, Criscuolo C, Filla A, Zuchner S, Bassi MT, Klopstock T, De Jonghe P, Bjorkhem I, Schule R. Hereditary spastic paraplegia type 5: natural history, biomarkers and a randomized controlled trial. Brain. 2017 Dec 1;140(12):3112-3127. doi: 10.1093/brain/awx273.
- Schule R, Wiethoff S, Martus P, Karle KN, Otto S, Klebe S, Klimpe S, Gallenmuller C, Kurzwelly D, Henkel D, Rimmele F, Stolze H, Kohl Z, Kassubek J, Klockgether T, Vielhaber S, Kamm C, Klopstock T, Bauer P, Zuchner S, Liepelt-Scarfone I, Schols L. Hereditary spastic paraplegia: Clinicogenetic lessons from 608 patients. Ann Neurol. 2016 Apr;79(4):646-58. doi: 10.1002/ana.24611. Epub 2016 Mar 11.
Historique de l'article
Article également disponible en Anglais, Allemand, Espagnol, Français, Italien, Portugais, Hindi, Hébreu, Arabe, and Suédois.
19 mars 2026 | Dernière version
1 mars 2026 | Publié à l'origine
Partagez vos pensées ou expériences avec les autres dans notre communautés de patients.
Inscrivez-vous à la newsletter Patient
Votre dose hebdomadaire de conseils de santé clairs et fiables - rédigés pour vous aider à vous sentir informé, confiant et maître de la situation.
En vous abonnant, vous acceptez notre Politique de confidentialité. Vous pouvez vous désabonner à tout moment. Nous ne vendons jamais vos données.

